Developing targeted therapeutics for hepatocellular carcinoma: a critical assessment of promising phase II agents

References

• Donne R, Lujambio A. The liver cancer immune microenvironment: therapeutic implications for hepatocellular carcinoma. Hepatology. 2023 May;77(5):1773–1796. doi: 10.1002/hep.32740
   PubMed Web of Science ®Google Scholar
• Llovet JM, Zucman-Rossi J, Pikarsky E, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016 Apr 14;2(1):16018. doi: 10.1038/nrdp.2016.18
   PubMedGoogle Scholar
• Zucman-Rossi J, Villanueva A, Nault JC, et al. Genetic landscape and biomarkers of hepatocellular carcinoma. Gastroenterology. 2015 Oct;149(5):1226–1239.e4. doi: 10.1053/j.gastro.2015.05.061
   PubMed Web of Science ®Google Scholar
• Singal AG, Kudo M, Bruix J. Breakthroughs in hepatocellular carcinoma therapies. Clin Gastroenterol And Hepatol. 2023 Jul;21(8):2135–2149. doi: 10.1016/j.cgh.2023.01.039
   PubMed Web of Science ®Google Scholar
• Llovet JM, Pinyol R, Kelley RK, et al. Molecular pathogenesis and systemic therapies for hepatocellular carcinoma. Nat Cancer. 2022 Apr 28;3(4):386–401. doi: 10.1038/s43018-022-00357-2
   PubMedGoogle Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008 Jul 24;359(4):378–390. doi: 10.1056/NEJMoa0708857
   PubMed Web of Science ®Google Scholar
• Singal AG, Llovet JM, Yarchoan M, et al. AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023 Dec;78(6):1922–1965. doi: 10.1097/HEP.0000000000000466
   PubMed Web of Science ®Google Scholar
• Abdelgalil AA, Alkahtani HM, Al-Jenoobi FI. Sorafenib. 2019. p. 239–266.
   Google Scholar
• Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020 May 14;382(20):1894–1905. doi: 10.1056/NEJMoa1915745
   PubMed Web of Science ®Google Scholar
• Yamashita T, Kudo M, Ikeda K, et al. REFLECT – a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset. J Gastroenterol. 2020 Jan 12;55(1):113–122. doi: 10.1007/s00535-019-01642-1
   PubMed Web of Science ®Google Scholar
• Facciorusso A, Tartaglia N, Villani R, et al. Lenvatinib versus sorafenib as first-line therapy of advanced hepatocellular carcinoma: a systematic review and meta-analysis. Am J Transl Res. 2021;13(4):2379–2387.
   PubMed Web of Science ®Google Scholar
• Yang X, Yang C, Zhang S, et al. Precision treatment in advanced hepatocellular carcinoma. Cancer Cell. 2024 Feb;42(2):180–197. doi: 10.1016/j.ccell.2024.01.007
   PubMed Web of Science ®Google Scholar
• Boyault S, Rickman DS, de Reyniès A, et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology. 2007 Jan;45(1):42–52. doi: 10.1002/hep.21467
   PubMed Web of Science ®Google Scholar
• Vij M, Calderaro J. Pathologic and molecular features of hepatocellular carcinoma: an update. World J Hepatol. 2021 Apr 27;13(4):393–410. doi: 10.4254/wjh.v13.i4.393
   PubMed Web of Science ®Google Scholar
• Craig AJ, von Felden J, Garcia-Lezana T, et al. Tumour evolution in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2020 Mar;17(3):139–152. doi: 10.1038/s41575-019-0229-4
   PubMed Web of Science ®Google Scholar
• Nault JC, Ningarhari M, Rebouissou S, et al. The role of telomeres and telomerase in cirrhosis and liver cancer. Nat Rev Gastroenterol Hepatol. 2019 Sep 28;16(9):544–558. doi: 10.1038/s41575-019-0165-3
   PubMed Web of Science ®Google Scholar
• Nault JC, Calderaro J, Di Tommaso L, et al. Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis. Hepatology. 2014 Dec 27;60(6):1983–1992. doi: 10.1002/hep.27372
   PubMed Web of Science ®Google Scholar
• Nault JC, Mallet M, Pilati C, et al. High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun. 2013 Jul 26;4(1):2218. doi: 10.1038/ncomms3218
   PubMedGoogle Scholar
• Torrecilla S, Sia D, Harrington AN, et al. Trunk mutational events present minimal intra- and inter-tumoral heterogeneity in hepatocellular carcinoma. J Hepatol. 2017 Dec;67(6):1222–1231. doi: 10.1016/j.jhep.2017.08.013
   PubMed Web of Science ®Google Scholar
• Sia D, Villanueva A, Friedman SL, et al. Liver cancer cell of origin, molecular class, and effects on patient prognosis. Gastroenterology. 2017 Mar;152(4):745–761. doi: 10.1053/j.gastro.2016.11.048
   PubMed Web of Science ®Google Scholar
• Castelli G, Pelosi E, Testa U. Liver cancer: molecular characterization, clonal evolution and cancer stem cells. Cancers (Basel). 2017 Sep 20;9(9):127. doi: 10.3390/cancers9090127
   PubMed Web of Science ®Google Scholar
• Bayo J, Fiore EJ, Dominguez LM, et al. A comprehensive study of epigenetic alterations in hepatocellular carcinoma identifies potential therapeutic targets. J Hepatol. 2019 Jul;71(1):78–90. doi: 10.1016/j.jhep.2019.03.007
   PubMed Web of Science ®Google Scholar
• Hlady RA, Sathyanarayan A, Thompson JJ, et al. Integrating the epigenome to identify drivers of hepatocellular carcinoma. Hepatology. 2019 Feb 5;69(2):639–652. doi: 10.1002/hep.30211
   PubMed Web of Science ®Google Scholar
• Cleary SP, Jeck WR, Zhao X, et al. Identification of driver genes in hepatocellular carcinoma by exome sequencing. Hepatology. 2013 Nov;58(5):1693–1702. doi: 10.1002/hep.26540
   PubMed Web of Science ®Google Scholar
• Senni N, Savall M, Cabrerizo Granados D, et al. β-catenin-activated hepatocellular carcinomas are addicted to fatty acids. Gut. 2019 Feb;68(2):322–334. doi: 10.1136/gutjnl-2017-315448
   PubMed Web of Science ®Google Scholar
• Rebouissou S, Nault JC. Advances in molecular classification and precision oncology in hepatocellular carcinoma. J Hepatol. 2020 Feb;72(2):215–229. doi: 10.1016/j.jhep.2019.08.017
   PubMed Web of Science ®Google Scholar
• Totoki Y, Tatsuno K, Covington KR, et al. Trans-ancestry mutational landscape of hepatocellular carcinoma genomes. Nat Genet. 2014 Dec 2;46(12):1267–1273. doi: 10.1038/ng.3126
   PubMed Web of Science ®Google Scholar
• Schulze K, Imbeaud S, Letouzé E, et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet. 2015 May 30;47(5):505–511. doi: 10.1038/ng.3252
   PubMed Web of Science ®Google Scholar
• Ahn S, Jang SJ, Shim JH, et al. Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification. Hepatology. 2014 Dec 22;60(6):1972–1982. doi: 10.1002/hep.27198
   PubMed Web of Science ®Google Scholar
• Ersahin T, Tuncbag N, Cetin-Atalay R. The PI3K/AKT/mTOR interactive pathway. Mol BioSyst. 2015 Jul;11(7):1946–1954. doi: 10.1039/C5MB00101C
   PubMedGoogle Scholar
• Wang Y, Deng B. Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers. Cancer Metastasis Rev. 2023 Sep;42(3):629–652. doi: 10.1007/s10555-023-10084-4
   PubMed Web of Science ®Google Scholar
• Sawey ET, Chanrion M, Cai C, et al. Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by oncogenomic screening. Cancer Cell. 2011 Mar;19(3):347–358. doi: 10.1016/j.ccr.2011.01.040
   PubMed Web of Science ®Google Scholar
• Chiang DY, Villanueva A, Hoshida Y, et al. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res. 2008 Aug 15;68(16):6779–6788. doi: 10.1158/0008-5472.CAN-08-0742
   PubMed Web of Science ®Google Scholar
• Garcia-Lezana T, Lopez-Canovas JL, Villanueva A. Signaling pathways in hepatocellular carcinoma. Adv Cancer Res. 2021;149:63–101.
   PubMed Web of Science ®Google Scholar
• Guichard C, Amaddeo G, Imbeaud S, et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet. 2012 Jun 6;44(6):694–698. doi: 10.1038/ng.2256
   PubMed Web of Science ®Google Scholar
• Sporn MB, Liby KT. NRF2 and cancer: the good, the bad and the importance of context. Nat Rev Cancer. 2012 Aug 19;12(8):564–571. doi: 10.1038/nrc3278
   PubMed Web of Science ®Google Scholar
• Sun H, Yang H, Mao Y. Personalized treatment for hepatocellular carcinoma in the era of targeted medicine and bioengineering. Front Pharmacol. 2023 May 5;14. doi: 10.3389/fphar.2023.1150151
   Web of Science ®Google Scholar
• Gluzman-Poltorak Z, Cohen T, Herzog Y, et al. Neuropilin-2 and neuropilin-1 are receptors for the 165-amino acid form of vascular endothelial growth factor (VEGF) and of placenta growth factor-2, but only neuropilin-2 functions as a receptor for the 145-amino acid form of VEGF. J Biol Chem. 2000 Jun;275(24):18040–18045. doi: 10.1074/jbc.M909259199
   PubMed Web of Science ®Google Scholar
• Matsumoto T, Mugishima H. Signal transduction via vascular endothelial growth factor (VEGF) receptors and their roles in Atherogenesis. J Atheroscler Thromb. 2006;13(3):130–135. doi: 10.5551/jat.13.130
   PubMed Web of Science ®Google Scholar
• Sia D, Alsinet C, Newell P, et al. VEGF signaling in cancer treatment. Curr Pharm Des. 2014 May 31;20(17):2834–2842. doi: 10.2174/13816128113199990590
   PubMed Web of Science ®Google Scholar
• Mantovani A. Molecular pathways linking inflammation and cancer. Curr Mol Med. 2010 Jun 1;10(4):369–373. doi: 10.2174/156652410791316968
   PubMed Web of Science ®Google Scholar
• Moser C, Lang SA, Stoeltzing O. The direct effects of anti–vascular endothelial growth factor therapy on tumor cells. Clin Colorectal Cancer. 2007 Jul;6(8):564–571. doi: 10.3816/CCC.2007.n.023
   PubMed Web of Science ®Google Scholar
• Rimassa L, Finn RS, Sangro B. Combination immunotherapy for hepatocellular carcinoma. J Hepatol. 2023 Aug;79(2):506–515. doi: 10.1016/j.jhep.2023.03.003
   PubMed Web of Science ®Google Scholar
• Sen DR, Kaminski J, Barnitz RA, et al. The epigenetic landscape of T cell exhaustion. Sci (1979). 2016 Dec 2;354(6316):1165–1169. doi: 10.1126/science.aae0491
   PubMed Web of Science ®Google Scholar
• Pardoll D. Cancer and the immune system: basic concepts and targets for intervention. Semin Oncol. 2015 Aug;42(4):523–538. doi: 10.1053/j.seminoncol.2015.05.003
   PubMed Web of Science ®Google Scholar
• Wei SC, Anang NAAS, Sharma R, et al. Combination anti–CTLA-4 plus anti–PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies. Proc Natl Acad Sci USA. 2019 Nov 5;116(45):22699–22709. doi: 10.1073/pnas.1821218116
   PubMed Web of Science ®Google Scholar
• Gavalas NG, Tsiatas M, Tsitsilonis O, et al. VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2. Br J Cancer. 2012 Nov 20;107(11):1869–1875. doi: 10.1038/bjc.2012.468
   PubMed Web of Science ®Google Scholar
• Voron T, Colussi O, Marcheteau E, et al. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J Exp Med. 2015 Feb 9;212(2):139–148. doi: 10.1084/jem.20140559
   PubMed Web of Science ®Google Scholar
• Dirkx AEM, Oude Egbrink MGA, Kuijpers MJE, et al. Tumor angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion molecule expression. Cancer Res. 2003 May 1;63(9):2322–2329.
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Chen HL, Girgis KR, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med. 1996 Oct 1;2(10):1096–1103. doi: 10.1038/nm1096-1096
   PubMed Web of Science ®Google Scholar
• Wada J, Suzuki H, Fuchino R, et al. The contribution of vascular endothelial growth factor to the induction of regulatory T-cells in malignant effusions. Anticancer Res. 2009 Mar;29(3):881–888.
   PubMed Web of Science ®Google Scholar
• Huang Y, Chen X, Dikov MM, et al. Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF. Blood. 2007 Jul 15;110(2):624–631. doi: 10.1182/blood-2007-01-065714
   PubMed Web of Science ®Google Scholar
• Khan KA, Kerbel RS. Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. Nat Rev Clin Oncol. 2018 May 13;15(5):310–324. doi: 10.1038/nrclinonc.2018.9
   PubMed Web of Science ®Google Scholar
• Xu J, Shen J, Gu S, et al. Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a nonrandomized, open-label, phase II trial. Clin Cancer Res. 2021 Feb 15;27(4):1003–1011. doi: 10.1158/1078-0432.CCR-20-2571
   PubMed Web of Science ®Google Scholar
• Zhang TQ, Geng ZJ, Zuo MX, et al. Camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and hepatic artery infusion chemotherapy for hepatocellular carcinoma in Barcelona clinic liver cancer stage C (TRIPLET): a phase II study. Signal Transduct Target Ther. 2023 Oct 27;8(1):413. doi: 10.1038/s41392-023-01663-6
   PubMed Web of Science ®Google Scholar
• Lyu N, Kong Y, Mu L, et al. Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma. J Hepatol. 2018 Jul;69(1):60–69. doi: 10.1016/j.jhep.2018.02.008
   PubMed Web of Science ®Google Scholar
• Li QJ, He MK, Chen HW, et al. Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: a randomized phase III trial. JCO. 2022 Jan 10;40(2):150–160. doi: 10.1200/JCO.21.00608
   Google Scholar
• Lai Z, He M, Bu X, et al. Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: a biomolecular exploratory, phase II trial. Eur J Cancer. 2022 Oct;174:68–77. doi: 10.1016/j.ejca.2022.07.005
   PubMed Web of Science ®Google Scholar
• Huang JT, Zhong JH, Zhang J, et al. Hepatectomy combined with apatinib and camrelizumab for CNLC stage IIIb hepatocellular carcinoma: a phase II trial protocol. BMJ Open. 2023 Sep 28;13(9):e067730. doi: 10.1136/bmjopen-2022-067730
   PubMed Web of Science ®Google Scholar
• Ren Z, Xu J, Bai Y, et al. ORIENT-32: updated characterization of response to sintilimab plus bevacizumab biosimilar (IBI305) vs sorafenib for unresectable hepatocellular carcinoma. JCO. 2023 Feb 1;41(4_suppl):570–570. doi: 10.1200/JCO.2023.41.4_suppl.570
   Google Scholar
• Zhou M, Zhu S, Xu C, et al. A phase Ib/II study of BLU-554, a fibroblast growth factor receptor 4 inhibitor in combination with CS1001, an anti-PD-L1, in patients with locally advanced or metastatic hepatocellular carcinoma. Invest New Drugs. 2023 Feb 10;41(1):162–167. doi: 10.1007/s10637-023-01335-w
   PubMed Web of Science ®Google Scholar
• Raja A, Park I, Haq F, et al. FGF19–FGFR4 signaling in hepatocellular carcinoma. Cells. 2019 Jun 4;8(6):536. doi: 10.3390/cells8060536
   PubMed Web of Science ®Google Scholar
• Chan SL, Schuler M, Kang YK, et al. A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors. J Exp Clin Cancer Res. 2022 Dec 2;41(1):189. doi: 10.1186/s13046-022-02383-5
   PubMed Web of Science ®Google Scholar
• Zhou Z, Chen X, Fu Y, et al. Characterization of FGF401 as a reversible covalent inhibitor of fibroblast growth factor receptor 4. Chem Commun. 2019;55(42):5890–5893. doi: 10.1039/C9CC02052G
   PubMed Web of Science ®Google Scholar
• Weiss A, Adler F, Buhles A, et al. FGF401, a first-in-class highly selective and potent FGFR4 inhibitor for the treatment of FGF19-driven hepatocellular cancer. Mol Cancer Ther. 2019 Dec 1;18(12):2194–2206. doi: 10.1158/1535-7163.MCT-18-1291
   PubMed Web of Science ®Google Scholar
• Fairhurst RA, Knoepfel T, Buschmann N, et al. Discovery of roblitinib (FGF401) as a reversible-covalent inhibitor of the kinase activity of fibroblast growth factor receptor 4. J Med Chem. 2020 Nov 12;63(21):12542–12573. doi: 10.1021/acs.jmedchem.0c01019
   PubMed Web of Science ®Google Scholar
• Shen G, Zheng F, Ren D, et al. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol. 2018 Dec 19;11(1):120. doi: 10.1186/s13045-018-0664-7
   PubMedGoogle Scholar
• Gao Y, Liu P, Shi R. Anlotinib as a molecular targeted therapy for tumors (Review). Oncol Lett. 2020 May 28;20(2):1001–1014. doi: 10.3892/ol.2020.11685
   PubMed Web of Science ®Google Scholar
• Syed YY. Anlotinib: first global approval. Drugs. 2018 Jul 26;78(10):1057–1062. doi: 10.1007/s40265-018-0939-x
   PubMed Web of Science ®Google Scholar
• Zhou M, Chen X, Zhang H, et al. China national medical products administration approval summary: anlotinib for the treatment of advanced non‐small cell lung cancer after two lines of chemotherapy. Cancer Commun. 2019 Dec 20;39(1):1–10. doi: 10.1186/s40880-019-0410-8
   Google Scholar
• Sun Y, Zhou A, Zhang W, et al. Anlotinib in the treatment of advanced hepatocellular carcinoma: an open-label phase II study (ALTER-0802 study). Hepatol Int. 2021 Jun 7;15(3):621–629. doi: 10.1007/s12072-021-10171-0
   PubMed Web of Science ®Google Scholar
• Han C, Ye S, Hu C, et al. Clinical activity and safety of penpulimab (anti-pd-1) with anlotinib as first-line therapy for unresectable hepatocellular carcinoma: an open-label, multicenter, phase ib/ii trial (AK105-203). Front Oncol. 2021 Jul 13;11. doi: 10.3389/fonc.2021.684867
   Web of Science ®Google Scholar
• Xue LS, Huang H, Zeng J, et al. Tislelizumab in combination with anlotinib as first-line treatment for unresectable hepatocellular carcinoma: a single-arm, phase II clinical trial. JCO. 2023 Feb 1;41(4_suppl):576–576. doi: 10.1200/JCO.2023.41.4_suppl.576
   Google Scholar
• Chen X, Li W, Wu X, et al. Safety and efficacy of sintilimab and anlotinib as first line treatment for advanced hepatocellular carcinoma (KEEP-G04): a single-arm phase 2 study. Front Oncol. 2022 May 31;12. doi: 10.3389/fonc.2022.909035
   Web of Science ®Google Scholar
• Zhang CS, Zeng ZM, Zhuo MY, et al. Anlotinib combined with toripalimab as first-line therapy for unresectable hepatocellular carcinoma: a prospective, multicenter, phase II study. Oncologist. 2023 Dec 11;28(12):e1239–47. doi: 10.1093/oncolo/oyad169
   PubMedGoogle Scholar
• Kang M, Xue F, Xu S, et al. Effectiveness and safety of anlotinib with or without S-1 in the treatment of patients with advanced hepatocellular carcinoma in a Chinese population: a prospective, phase 2 study. Radiol Oncol. 2023 Sep 1;57(3):405–410. doi: 10.2478/raon-2023-0036
   PubMed Web of Science ®Google Scholar
• Chhetri P. Current development of anti-cancer drug S-1. JCDR. 2016. doi: 10.7860/JCDR/2016/19345.8776
   Google Scholar
• Fishman P, Stemmer SM, Bareket-Samish A, et al. Targeting the A3 adenosine receptor to treat hepatocellular carcinoma: anti-cancer and hepatoprotective effects. Purinergic Signal. 2023 Sep 13;19(3):513–522. doi: 10.1007/s11302-023-09925-2
   PubMed Web of Science ®Google Scholar
• Madi L, Ochaion A, Rath-Wolfson L, et al. The A3 adenosine receptor is highly expressed in tumor versus normal cells. Clin Cancer Res. 2004 Jul 1;10(13):4472–4479. doi: 10.1158/1078-0432.CCR-03-0651
   PubMed Web of Science ®Google Scholar
• Stemmer SM, Benjaminov O, Medalia G, et al. CF102 For the treatment of hepatocellular carcinoma: a phase I/II, open-label, dose-escalation study. Oncologist. 2013 Jan 1;18(1):25–26. doi: 10.1634/theoncologist.2012-0211
   PubMed Web of Science ®Google Scholar
• Stemmer SM, Manojlovic NS, Marinca MV, et al. Namodenoson in advanced hepatocellular carcinoma and child–Pugh B cirrhosis: randomized placebo-controlled clinical trial. Cancers (Basel). 2021 Jan 7;13(2):187. doi: 10.3390/cancers13020187
   PubMed Web of Science ®Google Scholar
• Yang C, Zhang H, Zhang L, et al. Evolving therapeutic landscape of advanced hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2023 Apr 11;20(4):203–222. doi: 10.1038/s41575-022-00704-9
   PubMed Web of Science ®Google Scholar
• Lin X, Pan F, Abudoureyimu M, et al. Aurora-A inhibitor synergistically enhances the inhibitory effect of anlotinib on hepatocellular carcinoma. Biochem Biophys Res Commun. 2024 Jan;690:149247. doi: 10.1016/j.bbrc.2023.149247
   PubMed Web of Science ®Google Scholar
• Nigg EA. Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol. 2001 Jan;2(1):21–32. doi: 10.1038/35048096
   PubMed Web of Science ®Google Scholar
• Zhou SF, Yuan CX, Zhou ZW, et al. Inhibition of mitotic Aurora kinase a by alisertib induces apoptosis and autophagy of human gastric cancer AGS and NCI-N78 cells. Drug Des Devel Ther. 2015 Jan;487:487. doi: 10.2147/DDDT.S74127
   Google Scholar
• Zhang C, Qu L, Lian S, et al. PRL-3 promotes ubiquitination and degradation of AURKA and colorectal cancer progression via dephosphorylation of FZR1. Cancer Res. 2019 Mar 1;79(5):928–940. doi: 10.1158/0008-5472.CAN-18-0520
   PubMed Web of Science ®Google Scholar
• Zhang W, Xia D, Li Z, et al. Aurora-A/ERK1/2/mTOR axis promotes tumor progression in triple-negative breast cancer and dual-targeting Aurora-A/mTOR shows synthetic lethality. Cell Death Dis. 2019 Aug 13;10(8):606. doi: 10.1038/s41419-019-1855-z
   PubMedGoogle Scholar
• Wang-Bishop L, Chen Z, Gomaa A, et al. Inhibition of AURKA reduces proliferation and survival of gastrointestinal cancer cells with activated KRAS by preventing activation of RPS6KB1. Gastroenterology. 2019 Feb;156(3):662–675.e7. doi: 10.1053/j.gastro.2018.10.030
   PubMed Web of Science ®Google Scholar
• Adhikari B, Bozilovic J, Diebold M, et al. PROTAC-mediated degradation reveals a non-catalytic function of AURORA-A kinase. Nat Chem Biol. 2020 Nov 28;16(11):1179–1188. doi: 10.1038/s41589-020-00652-y
   PubMed Web of Science ®Google Scholar
• Yin Y, Yuan X, Gao H, et al. Nanoformulations of small molecule protein tyrosine kinases inhibitors potentiate targeted cancer therapy. Int J Pharm. 2020 Jan 5;573:118785. doi: 10.1016/j.ijpharm.2019.118785
   PubMedGoogle Scholar
• Su C, Liu Y, Li R, et al. Absorption, distribution, metabolism and excretion of the biomaterials used in Nanocarrier drug delivery systems. Adv Drug Deliv Rev. 2019 Mar;143:97–114. doi: 10.1016/j.addr.2019.06.008
   PubMed Web of Science ®Google Scholar
• Li X, Wang L, Wang L, et al. Overcoming therapeutic failure in osteosarcoma via Apatinib-encapsulated hydrophobic poly(ester amide) nanoparticles. Biomater Sci. 2020 Oct 27;8(21):5888–5899. doi: 10.1039/D0BM01296C
   PubMed Web of Science ®Google Scholar
• Zhang Y, Chen H, Feng N, et al. Construction and antitumor effects of antitumor micelles with cyclic RGD-modified anlotinib. Nanomed: Nanotechnol, Biol And Med. 2020 Aug;28:102224. doi: 10.1016/j.nano.2020.102224
   PubMed Web of Science ®Google Scholar
• Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol. 2021 Jun;18(6):327–344. doi: 10.1038/s41571-021-00470-8
   PubMed Web of Science ®Google Scholar
• Fuentes-Antrás J, Genta S, Vijenthira A, et al. Antibody–drug conjugates: in search of partners of choice. Trends Cancer. 2023 Apr;9(4):339–354. doi: 10.1016/j.trecan.2023.01.003
   PubMed Web of Science ®Google Scholar
• Kong FE, Li GM, Tang YQ, et al. Targeting tumor lineage plasticity in hepatocellular carcinoma using an anti-CLDN6 antibody-drug conjugate. Sci Transl Med. 2021 Feb 3;13(579). doi: 10.1126/scitranslmed.abb6282
   Web of Science ®Google Scholar
• Fu Y, Urban DJ, Nani RR, et al. Glypican‐3‐specific antibody drug conjugates targeting hepatocellular carcinoma. Hepatology. 2019 Aug 19;70(2):563–576. doi: 10.1002/hep.30326
   PubMed Web of Science ®Google Scholar
• An S, Zhang D, Zhang Y, et al. GPC3-targeted immunoPET imaging of hepatocellular carcinomas. Eur J Nucl Med Mol Imaging. 2022 Jul 11;49(8):2682–2692. doi: 10.1007/s00259-022-05723-x
   PubMed Web of Science ®Google Scholar
• Zhang FK, Ni QZ, Wang K, et al. Targeting USP9X–AMPK axis in ARID1A-Deficient hepatocellular carcinoma. Cell Mol Gastroenterol Hepatol. 2022;14(1):101–127. doi: 10.1016/j.jcmgh.2022.03.009
   PubMed Web of Science ®Google Scholar
• Lee H, Zandkarimi F, Zhang Y, et al. Energy-stress-mediated AMPK activation inhibits ferroptosis. Nat Cell Biol. 2020 Feb 6;22(2):225–234. doi: 10.1038/s41556-020-0461-8
   PubMed Web of Science ®Google Scholar
• Liu Z, Zhang G, Huang S, et al. Induction of apoptosis in hematological cancer cells by dorsomorphin correlates with BAD upregulation. Biochem Biophys Res Commun. 2020 Feb;522(3):704–708. doi: 10.1016/j.bbrc.2019.11.157
   PubMed Web of Science ®Google Scholar
• Ali JL, Lagasse BJ, Minuk AJ, et al. Differential cellular responses induced by dorsomorphin and LDN-193189 in chemotherapy-sensitive and chemotherapy-resistant human epithelial ovarian cancer cells. Int J Cancer. 2015 Mar 26;136(5):E455–69. doi: 10.1002/ijc.29220
   PubMed Web of Science ®Google Scholar
• Liu X, Chhipa RR, Nakano I, et al. The AMPK inhibitor compound C is a Potent AMPK-Independent antiglioma agent. Mol Cancer Ther. 2014 Mar 1;13(3):596–605. doi: 10.1158/1535-7163.MCT-13-0579
   PubMed Web of Science ®Google Scholar
• Du D, Liu C, Qin M, et al. Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma. Acta Pharm Sin B. 2022 Feb;12(2):558–580. doi: 10.1016/j.apsb.2021.09.019
   PubMed Web of Science ®Google Scholar
• Okano N, Naruge D, Kawai K, et al. First-in-human phase I study of JPH203, an L-type amino acid transporter 1 inhibitor, in patients with advanced solid tumors. Invest New Drugs. 2020 Oct;38(5):1495–1506. doi: 10.1007/s10637-020-00924-3
   PubMed Web of Science ®Google Scholar
• Che L, Paliogiannis P, Cigliano A, et al. Pathogenetic, prognostic, and therapeutic role of fatty acid synthase in human hepatocellular carcinoma. Front Oncol. 2019 Dec 11;9. doi: 10.3389/fonc.2019.01412
   Web of Science ®Google Scholar
• Lally JSV, Ghoshal S, DePeralta DK, et al. Inhibition of acetyl-CoA carboxylase by phosphorylation or the inhibitor ND-654 suppresses lipogenesis and hepatocellular carcinoma. Cell Metab. 2019 Jan;29(1):174–182.e5. doi: 10.1016/j.cmet.2018.08.020
   PubMed Web of Science ®Google Scholar
• Menendez JA, Lupu R. Fatty acid synthase (FASN) as a therapeutic target in breast cancer. Expert Opin Ther Targets. 2017 Nov;21(11):1001–1016. doi: 10.1080/14728222.2017.1381087
   PubMed Web of Science ®Google Scholar
• Ho WJ, Zhu Q, Durham J, et al. Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity. Nat Cancer. 2021 Jul 29;2(9):891–903. doi: 10.1038/s43018-021-00234-4
   PubMedGoogle Scholar
• Chick RC, Ruff SM, Pawlik TM. Neoadjuvant systemic therapy for hepatocellular carcinoma. Front Immunol. 2024 Mar 1;15. doi: 10.3389/fimmu.2024.1355812
   PubMed Web of Science ®Google Scholar
• Facciorusso A, Del Prete V, Crucinio N, et al. Angiotensin receptor blockers improve survival outcomes after radiofrequency ablation in hepatocarcinoma patients. J Gastroenterol Hepatol. 2015 Nov 12;30(11):1643–1650. doi: 10.1111/jgh.12988
   PubMed Web of Science ®Google Scholar
• Casadei-Gardini A, Rimini M, Tada T, et al. Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population. Eur J Cancer. 2023 Feb;180:9–20. doi: 10.1016/j.ejca.2022.11.017
   PubMed Web of Science ®Google Scholar